Giving Tuesday Giving Tuesday

Donate today and help mobilize high performing teams from 10 vital program areas as they train future leaders, provide passionate care, and support patients and their families in their toughest moments.

Marijuana worsens MS brain deterioration

March 28, 2011

New research proves that prolonged use of cannabis in multiple sclerosis (MS) patients results in even poorer performance on cognitive skills already affected by MS.

"MS is a disease that affects the brain and is associated with cognitive deterioration as it is. Prolonged inhaled or ingested (‘street') cannabis use is shown to significantly worsen one's attention span, speed of thinking and processing information, working memory, executive functions and visuospatial skills," says Dr. Anthony Feinstein, lead investigator of the study and neuropsychiatrist at Sunnybrook. "What this tells us is that MS patients need to be made aware of these effects on personal, social and occupational functioning, and weigh whatever benefits with the very real cognitive side effects they will likely experience from long-term cannabis use."

Two groups of MS patients — 25 cannabis users and 25 non-users — were both tested using various cognitive skills testing including neuropsychological tests and interviews, as well as a psychiatric anxiety and depression scale.

Patients between the ages of 18 to 65 with confirmed MS were recruited from MS clinics affiliated with the University of Toronto. The average duration of marijuana use was 26 years. A total of 72 percent of users reported smoking marijuana on a daily basis while 24 percent reported weekly use and one person reported bi-weekly use.

In addition to performing significantly more poorly than non-users in the cognitive functioning skills mentioned above, the cannabis users were also twice as likely as non-users to be classified as globally cognitively impaired. There were no differences in psychiatric diagnoses for depression and anxiety.

"Given that about 40 to 60 per cent of MS patients have problems with cognitive function to begin with, any drug that may add to this burden is cause for concern," adds Dr. Feinstein.

PDF / View full media release »